Nutriband reports Q2 EPS ($2.12) vs. (15c) last year

Reports Q2 revenue $622,452 vs. $442,830 last year. The company said, “The company reported a strong cash position at quarter end, reinforcing its ability to advance the development of its lead product, AVERSA Fentanyl which has been granted a Type C meeting on September 18th. Nutriband (NTRB) is continuing to expand its kinesiology tape contract manufacturing services through its Pocono Pharma subsidiary. The company produced a record six months, reporting revenue of $1,289,884, up 50.87% YOY. Progress continues on the development of AVERSA Fentanyl, Nutriband is reminding exiting shareholders and updating new shareholders on its development pathway, emphasizing that the NDA will primarily rely on data from a single phase 1 Human Abuse Potential study. Importantly, no Phase 2 or Phase 3 clinical trials will be required before submission. If approved, AVERSA Fentanyl could become the first and only abuse-deterrent transdermal patch available globally. AVERSA Fentanyl is estimated to have the potential to reach peak annual sales of $80M-$200M, according to a market analysis report from Health Advances. AVERSA Buprenorphine, which is the company’s second application for AVERSA, is projected to reach peak annual sales of up to $130M. As of July 31, 2025, Nutriband’s cash reserves stand at $6.9M, supporting the company’s ongoing development and commercialization efforts for AVERSA Fentanyl. The company’s total assets are valued at $10.17M, with stockholders’ equity amounting to $8.5M.”